There is a critical need for curative therapy for hepatitis b (HBV). This program will systematically review the various approaches to achieving this goal. Attendees will gain a greater appreciation for the challenges in developing new HBV therapies and discover where new therapies will fit into the future treatment landscape for this disease.Jordan J. Feld Jordan J. Feld, MD, MPH, FAASLD attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr.

Gain a solid background on the mechanisms that activate and potentiate hepatic injury, inflammation and fibrosis through an in-depth presentation of the different yet related basic molecular mechanisms that underlie various types of hepatic damage.Melanie J. Scott Xiaoxia Li Nissiam Hay Yingzi Yang

Join international portal hypertension experts for a critical review of several invasive interventions performed in patients with the disease. This session will look at potential situations that may interfere with the accuracy and reproducibility of hepatic venous pressure gradient and portal pressure gradient measurements in the course of TIPS. It will also discuss recommendations for standardizing the procedure.

As the number and type of drugs used to treat pediatric illnesses proliferate, and the push to make new drugs available for children gains speed, understanding how to recognize drug-induced liver injury is increasingly important for pediatric liver providers. This program will focus on challenges and opportunities associated with the diagnosis and management of DILI that are unique to the pediatric population. Clinical presentations include surreptitious elevation of serum aminotransferase levels, acute liver injury with or without acute liver failure, and chronic liver disease.Binita M.

A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.Jay H. Hoofnagle Jay H.

20 October 2017

Vikas Gupta, Robert E. Schwartz, Nicole Shen, Robert S. Brown, Russell Rosenblatt, Nicholas Russo, Rachel Niec, Shirley Cohen‐Mekelburg, Saurabh Mukewar – 20 October 2017

Vikas Gupta, Robert E. Schwartz, Nicole Shen, Robert S. Brown, Russell Rosenblatt, Nicholas Russo, Rachel Niec, Shirley Cohen‐Mekelburg, Saurabh Mukewar – 20 October 2017

20 October 2017

20 October 2017